Dual TYK2/JAK1 Inhibition by Brepocitinib Reprograms Synoviocyte Pathobiology: Mechanistic Insights Into Targeted Therapy for Rheumatoid Arthritis
Brepocitinib exerts multi-faceted effects on RA synoviocytes by simultaneously inhibiting inflammatory signaling, suppressing cytokine expression, restoring apoptotic sensitivity, and reducing migratory potential. These findings provide mechanistic support for brepocitinib as a targeted therapeutic agent in RA.
Authors
- Andromeda M. Nauli (ORCID: https://orcid.org/0000-0002-3990-6040)
- Surya M. Nauli
- Zahra Zahid Piracha
- Umar Saeed
Institutions
- Western Michigan University (US)
- Foundation University Islamabad (PK)
- Cyprus International University (CY)
- Chapman University (US)
- Korea University (KR)
- Korea University (JP)
- Széchenyi István University (HU)
Publication Details
- Journal
- Iranian journal of pharmaceutical research
- Published
- 2026-02-01
- DOI
- https://doi.org/10.5812/ijpr-166019
- Primary Topic
- Cytokine Signaling Pathways and Interactions
- Type
- article
- Field-Weighted Citation Impact
- 0.00